中华胃肠外科杂志
中華胃腸外科雜誌
중화위장외과잡지
CHINESE JOURNAL OF GASTROINTESTINAL SURGERY
2010年
5期
366-370
,共5页
蒋敬庭%吴昌平%沈月平%郑璐%吴骏%季枚%徐斌%陈陆俊%吴雨岗%郑晓%朱一蓓%LU Binfeng%张学光
蔣敬庭%吳昌平%瀋月平%鄭璐%吳駿%季枚%徐斌%陳陸俊%吳雨崗%鄭曉%硃一蓓%LU Binfeng%張學光
장경정%오창평%침월평%정로%오준%계매%서빈%진륙준%오우강%정효%주일배%LU Binfeng%장학광
胃肿瘤%共刺激分子%细胞因子诱导的杀伤细胞%免疫治疗%预后
胃腫瘤%共刺激分子%細胞因子誘導的殺傷細胞%免疫治療%預後
위종류%공자격분자%세포인자유도적살상세포%면역치료%예후
Stomach neoplasms%Costimulatory molecules%Cytokine-induced killer cells%Immunotherapy%Prognosis
目的 评价共刺激分子B7-H4表达对细胞因子诱导的杀伤细胞(CIK细胞)过继免疫治疗胃癌患者后预后的影响.方法 采用回顾性队列分析156例胃癌的临床资料,并按其治疗情况分为对照组(81例,单纯化疗)和试验组(75例,化疗联合CIK细胞治疗).对胃癌患者组织进行B7-H4免疫组织化学染色,并比较B7-H4不同表达情况下,对照组与试验组治疗后无瘤生存率的差异.结果 对照组和试验组间各临床病理资料的差异无统计学意义(p>0.05).两组术后中位无瘤生存时间分别为18.0个月和45.0个月(χ~2=11.631,P=0.001),术后中位总体生存时间分别为27.0个月和49.0个月(χ~2=10.907,P=0.001),差异均有统计学意义.86例B7-H4低表达者中,采用单纯化疗和CIK联合治疗后中位无瘤生存时间分别为32.0个月和62.0个月.差异有统计学意义(χ~2=4.663,P=0.03);70例B7-H4高表达者中,采用单纯化疗和CIK联合治疗后中位无瘤生存时间分别11.0个月和18.0个月,差异有统计学意义(χ~2=11.971,P=0.001).结论 采用化学治疗联合CIK细胞回输治疗胃癌,无论B7-H4高表达还是低表达,均可显著延长胃癌患者的无瘤生存时间.
目的 評價共刺激分子B7-H4錶達對細胞因子誘導的殺傷細胞(CIK細胞)過繼免疫治療胃癌患者後預後的影響.方法 採用迴顧性隊列分析156例胃癌的臨床資料,併按其治療情況分為對照組(81例,單純化療)和試驗組(75例,化療聯閤CIK細胞治療).對胃癌患者組織進行B7-H4免疫組織化學染色,併比較B7-H4不同錶達情況下,對照組與試驗組治療後無瘤生存率的差異.結果 對照組和試驗組間各臨床病理資料的差異無統計學意義(p>0.05).兩組術後中位無瘤生存時間分彆為18.0箇月和45.0箇月(χ~2=11.631,P=0.001),術後中位總體生存時間分彆為27.0箇月和49.0箇月(χ~2=10.907,P=0.001),差異均有統計學意義.86例B7-H4低錶達者中,採用單純化療和CIK聯閤治療後中位無瘤生存時間分彆為32.0箇月和62.0箇月.差異有統計學意義(χ~2=4.663,P=0.03);70例B7-H4高錶達者中,採用單純化療和CIK聯閤治療後中位無瘤生存時間分彆11.0箇月和18.0箇月,差異有統計學意義(χ~2=11.971,P=0.001).結論 採用化學治療聯閤CIK細胞迴輸治療胃癌,無論B7-H4高錶達還是低錶達,均可顯著延長胃癌患者的無瘤生存時間.
목적 평개공자격분자B7-H4표체대세포인자유도적살상세포(CIK세포)과계면역치료위암환자후예후적영향.방법 채용회고성대렬분석156례위암적림상자료,병안기치료정황분위대조조(81례,단순화료)화시험조(75례,화료연합CIK세포치료).대위암환자조직진행B7-H4면역조직화학염색,병비교B7-H4불동표체정황하,대조조여시험조치료후무류생존솔적차이.결과 대조조화시험조간각림상병리자료적차이무통계학의의(p>0.05).량조술후중위무류생존시간분별위18.0개월화45.0개월(χ~2=11.631,P=0.001),술후중위총체생존시간분별위27.0개월화49.0개월(χ~2=10.907,P=0.001),차이균유통계학의의.86례B7-H4저표체자중,채용단순화료화CIK연합치료후중위무류생존시간분별위32.0개월화62.0개월.차이유통계학의의(χ~2=4.663,P=0.03);70례B7-H4고표체자중,채용단순화료화CIK연합치료후중위무류생존시간분별11.0개월화18.0개월,차이유통계학의의(χ~2=11.971,P=0.001).결론 채용화학치료연합CIK세포회수치료위암,무론B7-H4고표체환시저표체,균가현저연장위암환자적무류생존시간.
Objective To investigate the influence of co-stimulatory molecules B7-H4 expression on prognosis of gastric cancer patients treated by cytokine-induced killer cells (CIK cells) adoptive immunotherapy. Methods Clinical data of 156 cases of gastric cancer patients were retrospectively analyzed.Patients were divided into chemotherapy group(n=81)and chemotherapy combined with CIK cell therapy group(n=75).B7-H4 expression was detected in the surgical specimens of gastric cancer patients by immunohistochemistry assay.Disease-free survival was compared between the chemotherapy group and the CIK group at different expression levels of B7-H4. Results The difference was not statistically significant in all clinical and pathological data between the chemotherapy group and the CIK treatment group(P>0.05).The postoperative median tumor-free survival in two groups was 18.0 and 45.0 months,respectively,and the difference was statistically significant(χ~2=11.631,P=0.001).The postoperative median survival time was 27.0 and 49.0 months,respectively,and the difference was statistically significant(χ~2=10.907,P=0.001).In 86 patients with low B7-H4 expression,the median tumor-free survival time was 32.0 and 62.0 months,respectively,and the difference was statistically significant(X2=4.663.P=0.03).In 70 patients with hish B7-H4 expression,the median tumor-free survival time was 11.0 and 18.0 months,respectively,and the difference was statistically significant (χ~2=11.971,P=0.001). Conclusion The median tumor-free survival time of patients with gastric cancer may be further improved by chemotherapy combined with CIK cell therapy,regardless of the level of B7-H4 expression.
